Literature DB >> 32459958

Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA.

Angelica V Medina-Cucurella1, Gary F Bammert2, William Dunkle2, Christopher Javens2, Yaqi Zhu2, Veronica T Mutchler2, Janet T Teel2, Caitlin A Stein1, Steve A Dunham2, Timothy A Whitehead1,3.   

Abstract

Interleukin-31 (IL-31) is a major protein involved in severe inflammatory skin disorders. Its signaling pathway is mediated through two type I cytokine receptors, IL-31RA (also known as the gp130-like receptor) and the oncostatin M receptor (OSMR). Understanding molecular details in these interactions would be helpful for developing antagonist anti-IL-31 monoclonal antibodies (mAbs) as potential therapies. Previous studies suggest that human IL-31 binds to IL-31RA and then recruits OSMR to form a ternary complex. In this model, OSMR cannot interact with IL-31 in the absence of IL-31RA. In this work, we show that feline IL-31 (fIL-31) binds independently with feline OSMR using surface plasmon resonance, an enzyme-linked immunosorbent assay, and yeast surface display. Moreover, competition experiments suggest that OSMR shares a partially overlapping epitope with IL-31RA. We then used deep mutational scanning to map the binding sites of both receptors on fIL-31. In agreement with previous studies of the human homologue, the binding site for IL31-RA contains fIL-31 positions E20 and K82, while the binding site for OSMR comprises the "PADNFERK" motif (P103-K110) and position G38. However, our results also revealed a new overlapping site, composed of positions R69, R72, P73, D76, D81, and E97, between both receptors that we called the "shared site". The conformational epitope of an anti-feline IL-31 mAb that inhibits both OSMR and IL-31RA also mapped to this shared site. Combined, our results show that fIL-31 binds IL-31RA and OSMR independently through a partially shared epitope. These results suggest reexamination of the putative canonical mechanisms for IL-31 signaling in higher animals.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32459958      PMCID: PMC7379511          DOI: 10.1021/acs.biochem.0c00176

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  30 in total

1.  Isolating and engineering human antibodies using yeast surface display.

Authors:  Ginger Chao; Wai L Lau; Benjamin J Hackel; Stephen L Sazinsky; Shaun M Lippow; K Dane Wittrup
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring.

Authors:  M H M Ezzat; Z E Hasan; K Y A Shaheen
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-03       Impact factor: 6.166

3.  GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor.

Authors:  Caroline Diveu; Eric Lelièvre; David Perret; Anne-Hélène Lagrue Lak-Hal; Josy Froger; Catherine Guillet; Sylvie Chevalier; François Rousseau; Amy Wesa; Laurence Preisser; Marie Chabbert; Jean-François Gauchat; Anne Galy; Hugues Gascan; Alain Morel
Journal:  J Biol Chem       Date:  2003-09-22       Impact factor: 5.157

4.  Molecular dissection of human interleukin-31-mediated signal transduction through site-directed mutagenesis.

Authors:  Sabine Le Saux; François Rousseau; Fabien Barbier; Elisa Ravon; Linda Grimaud; Yannic Danger; Josy Froger; Sylvie Chevalier; Hugues Gascan
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

5.  Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody.

Authors:  K E Lewis; M S Holdren; M F Maurer; S Underwood; B Meengs; S H Julien; K A Byrnes-Blake; J A Freeman; T R Bukowski; A C Wolf; N B Hamacher; M W Rixon; S R Dillon
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-08-08       Impact factor: 6.166

6.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Authors:  Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606

7.  Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing.

Authors:  Caitlin A Kowalsky; Matthew S Faber; Aritro Nath; Hailey E Dann; Vince W Kelly; Li Liu; Purva Shanker; Ellen K Wagner; Jennifer A Maynard; Christina Chan; Timothy A Whitehead
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

8.  I-TASSER server for protein 3D structure prediction.

Authors:  Yang Zhang
Journal:  BMC Bioinformatics       Date:  2008-01-23       Impact factor: 3.169

9.  High-resolution sequence-function mapping of full-length proteins.

Authors:  Caitlin A Kowalsky; Justin R Klesmith; James A Stapleton; Vince Kelly; Nolan Reichkitzer; Timothy A Whitehead
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.